🔎 Trials Near Me

Home › Ovarian Cancer › Missouri

Ovarian Cancer clinical trials in Missouri

41 studies for Ovarian Cancer are looking for participants at sites in Missouri.

Cities in Missouri

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Saint Luke's Hospital of Kansas City, Kansas City
  • Washington University School of Medicine, St Louis
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Oct 5, 2026 · NCT06995898

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 5, 2026 · NCT06915025

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Washington University School of Medicine, St Louis
  • and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Saint Francis Medical Center, Cape Girardeau
  • Saint Luke's Hospital, Chesterfield
  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • and 13 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Washington University Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Washington University, School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Cox Medical Center South /ID# 274826, Springfield
  • Mercy David C. Pratt Cancer Center /ID# 275655, St Louis
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Washington University, St Louis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • University of Missouri Hospital, Columbia
  • HCA Midwest Kansas City, MidAmerica Division, Inc., Kansas City
  • Cox Medical Center North, Springfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Washington Univ. School of Medicine, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Mercy Hospital St. Louis - David C. Pratt Cancer Center, St Louis
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Washington University, St Louis
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Washington University School of Medicine, St Louis
  • Mercy Hospital St. Louis, St Louis
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Washington University School of Medicine, St Louis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Washington University, Siteman Cancer Center, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Mercy Hospital Springfield, Springfield
  • Washington University School of Medicine, St Louis
  • Missouri Baptist Medical Center, St Louis
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Central Care Cancer Center - Bolivar, Bolivar
  • Cox Cancer Center Branson, Branson
  • and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314

IDOV-Immune for Advanced Solid Tumors

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Washington University, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Washington University School of Medicine Obstetrics and Gynecology, St Louis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #110, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06545942

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 334, Kansas City
  • 521, St Louis
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Saint Luke's Cancer Institute, Kansas City
  • Washington University, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • Saint Louis University, St Louis
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT06710756

Integrated Cancer Repository for Cancer Research

  • Saint Luke's Cancer Institute, East, Kansas City
  • Saint Luke's Cancer Institute, Kansas City
  • Saint Luke's Cancer Institute, Kansas City North, Kansas City
  • and 3 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Washington University, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

  • Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 1
Ages 18 and older · Women · Updated May 28, 2026 · NCT06930755

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

  • Research site, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06386146

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center North, Kansas City
  • University of Kansas Cancer Center Lee's Summit, Lee's Summit
  • and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

  • Site 0111, St Louis
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  • Washington University Medical Center, St Louis
Recruiting
Ages 25 to 50 · Women · Updated Apr 6, 2026 · NCT04294927

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • Washington University, St Louis
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.